{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:07:52Z","timestamp":1790712472906,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T00:00:00Z","timestamp":1673049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T00:00:00Z","timestamp":1673049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Glioblastoma (GBM) infrequently recurs in the infratentorial region. Such Infratentorial recurrence (ITR) has some clinically unique characteristics, such as presenting unspecific symptoms and providing patients a chance to receive additional radiotherapy. However, the clinical significances of ITR are not well studied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We reviewed newly diagnosed isocitrate dehydrogenase (IDH)-wildtype GBM patients treated at our institution between October 2008 and December 2018. ITR was defined as any type of recurrence in GBM, including dissemination or distant recurrence, which primarily developed in the supratentorial region and recurred in the infratentorial region.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 134 patients with newly diagnosed IDH-wildtype GBM, six (4.5%) were classified as having ITR. There was no significant difference in median duration from the first surgery to ITR development between patients with and without ITR (12.2 vs. 10.2\u00a0months,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.65). The primary symptoms of ITR were gait disturbance (100%,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20096), dizziness (50.0%,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20093), nausea (33.3%,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20092), and cerebellar mutism (16.7%,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091). In four cases (66.7%), symptoms were presented before ITR development. All patients received additional treatments for ITR. The median post-recurrence survival (PRS) of ITR patients was significantly shorter than that of general GBM patients (5.5 vs. 9.1\u00a0months,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.023). However, chemoradiotherapy contributed to palliating symptoms such as nausea.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ITR is a severe recurrence type in GBM patients. Its symptoms are neurologically unspecific and can be overlooked or misdiagnosed as side effects of treatments. Carefully checking the infratentorial region, especially around the fourth ventricle, is essential during the GBM patient follow-up.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-022-03047-9","type":"journal-article","created":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T23:26:39Z","timestamp":1673047599000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Clinical characteristics and prognosis of Glioblastoma patients with infratentorial recurrence"],"prefix":"10.1186","volume":"23","author":[{"given":"Daisuke","family":"Kawauchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Honda-Kitahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuji","family":"Miyakita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamichi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Yanagisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukie","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyu","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Ichimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Narita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,7]]},"reference":[{"key":"3047_CR1","doi-asserted-by":"publisher","first-page":"590648","DOI":"10.3389\/fonc.2020.590648","volume":"10","author":"H Jiang","year":"2020","unstructured":"Jiang H, Yu K, Li M, Cui Y, Ren X, Yang C, Zhao X, Lin S. Classification of progression patterns in glioblastoma: analysis of predictive factors and clinical implications. Front Oncol. 2020;10:590648. https:\/\/doi.org\/10.3389\/fonc.2020.590648.","journal-title":"Front Oncol"},{"key":"3047_CR2","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.wneu.2017.04.053","volume":"103","author":"M Rapp","year":"2017","unstructured":"Rapp M, Baernreuther J, Turowski B, Steiger HJ, Sabel M, Kamp MA. Recurrence pattern analysis of primary glioblastoma. World Neurosurg. 2017;103:733\u201340. https:\/\/doi.org\/10.1016\/j.wneu.2017.04.053.","journal-title":"World Neurosurg"},{"key":"3047_CR3","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.2008.19.4969","volume":"27","author":"AA Brandes","year":"2009","unstructured":"Brandes AA, Tosoni A, Franceschi E, Sotti G, Frezza G, Amista P, Morandi L, Spagnolli F, Ermani M. Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status. J Clin Oncol. 2009;27:1275\u20139. https:\/\/doi.org\/10.1200\/JCO.2008.19.4969.","journal-title":"J Clin Oncol"},{"key":"3047_CR4","doi-asserted-by":"publisher","first-page":"20120414","DOI":"10.1259\/bjr.20120414","volume":"86","author":"J Sherriff","year":"2013","unstructured":"Sherriff J, Tamangani J, Senthil L, Cruickshank G, Spooner D, Jones B, Brookes C, Sanghera P. Patterns of relapse in glioblastoma multiforme following concomitant chemoradiotherapy with temozolomide. Br J Radiol. 2013;86:20120414. https:\/\/doi.org\/10.1259\/bjr.20120414.","journal-title":"Br J Radiol"},{"key":"3047_CR5","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/neuonc\/4.2.129","volume":"4","author":"ZR Cohen","year":"2002","unstructured":"Cohen ZR, Hassenbusch SJ, Maor MH, Pfeffer RM, Ram Z. Intractable vomiting from glioblastoma metastatic to the fourth ventricle: three case studies. Neuro Oncol. 2002;4:129\u201333. https:\/\/doi.org\/10.1093\/neuonc\/4.2.129.","journal-title":"Neuro Oncol"},{"key":"3047_CR6","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23:1231\u201351. https:\/\/doi.org\/10.1093\/neuonc\/noab106.","journal-title":"Neuro Oncol"},{"key":"3047_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s10014-014-0186-0","volume":"32","author":"H Arita","year":"2015","unstructured":"Arita H, Narita Y, Matsushita Y, Fukushima S, Yoshida A, Takami H, Miyakita Y, Ohno M, Shibui S, Ichimura K. Development of a robust and sensitive pyrosequencing assay for the detection of IDH1\/2 mutations in gliomas. Brain Tumor Pathol. 2015;32:22\u201330. https:\/\/doi.org\/10.1007\/s10014-014-0186-0.","journal-title":"Brain Tumor Pathol"},{"key":"3047_CR8","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00401-013-1141-6","volume":"126","author":"H Arita","year":"2013","unstructured":"Arita H, Narita Y, Fukushima S, Tateishi K, Matsushita Y, Yoshida A, Miyakita Y, Ohno M, Collins VP, Kawahara N, Shibui S, Ichimura K. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol. 2013;126:267\u201376. https:\/\/doi.org\/10.1007\/s00401-013-1141-6.","journal-title":"Acta Neuropathol"},{"key":"3047_CR9","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s13014-019-1389-7","volume":"14","author":"M Ohno","year":"2019","unstructured":"Ohno M, Miyakita Y, Takahashi M, Igaki H, Matsushita Y, Ichimura K, Narita Y. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged >\/= 75 years. Radiat Oncol. 2019;14:200. https:\/\/doi.org\/10.1186\/s13014-019-1389-7.","journal-title":"Radiat Oncol"},{"key":"3047_CR10","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1093\/neuonc\/noz216","volume":"22","author":"MR Drumm","year":"2020","unstructured":"Drumm MR, Dixit KS, Grimm S, Kumthekar P, Lukas RV, Raizer JJ, Stupp R, Chheda MG, Kam KL, McCord M, Sachdev S, Kruser T, Steffens A, Javier R, McCortney K, Horbinski C. Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas. Neuro Oncol. 2020;22:470\u20139. https:\/\/doi.org\/10.1093\/neuonc\/noz216.","journal-title":"Neuro Oncol"},{"key":"3047_CR11","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s00234-011-0878-7","volume":"53","author":"HG Kwon","year":"2011","unstructured":"Kwon HG, Hong JH, Hong CP, Lee DH, Ahn SH, Jang SH. Dentatorubrothalamic tract in human brain: diffusion tensor tractography study. Neuroradiology. 2011;53:787\u201391. https:\/\/doi.org\/10.1007\/s00234-011-0878-7.","journal-title":"Neuroradiology"},{"key":"3047_CR12","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/nn1075","volume":"6","author":"TE Behrens","year":"2003","unstructured":"Behrens TE, Johansen-Berg H, Woolrich MW, Smith SM, Wheeler-Kingshott CA, Boulby PA, Barker GJ, Sillery EL, Sheehan K, Ciccarelli O, Thompson AJ, Brady JM, Matthews PM. Non-invasive mapping of connections between human thalamus and cortex using diffusion imaging. Nat Neurosci. 2003;6:750\u20137. https:\/\/doi.org\/10.1038\/nn1075.","journal-title":"Nat Neurosci"},{"key":"3047_CR13","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1083\/jcb.144.2.373","volume":"144","author":"AT Belien","year":"1999","unstructured":"Belien AT, Paganetti PA, Schwab ME. Membrane-type 1 matrix metalloprotease (MT1-MMP) enables invasive migration of glioma cells in central nervous system white matter. J Cell Biol. 1999;144:373\u201384. https:\/\/doi.org\/10.1083\/jcb.144.2.373.","journal-title":"J Cell Biol"},{"key":"3047_CR14","doi-asserted-by":"publisher","first-page":"24","DOI":"10.14791\/btrt.2017.5.1.24","volume":"5","author":"MN Khan","year":"2017","unstructured":"Khan MN, Poulin A, Essig M. Fourth ventricular lesions in metastatic gliomas: a rare predilection? Brain Tumor Res Treat. 2017;5:24\u20139. https:\/\/doi.org\/10.14791\/btrt.2017.5.1.24.","journal-title":"Brain Tumor Res Treat"},{"key":"3047_CR15","doi-asserted-by":"publisher","first-page":"175628641875961","DOI":"10.1177\/1756286418759618","volume":"11","author":"A Pellerino","year":"2018","unstructured":"Pellerino A, Bertero L, Ruda R, Soffietti R. Neoplastic meningitis in solid tumors: from diagnosis to personalized treatments. Ther Adv Neurol Disord. 2018;11:1756286418759618. https:\/\/doi.org\/10.1177\/1756286418759618.","journal-title":"Ther Adv Neurol Disord"},{"key":"3047_CR16","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s11060-014-1592-1","volume":"120","author":"JJ Mandel","year":"2014","unstructured":"Mandel JJ, Yust-Katz S, Cachia D, Wu J, Liu D, de Groot JF, Yung AW, Gilbert MR. Leptomeningeal dissemination in glioblastoma; an inspection of risk factors, treatment, and outcomes at a single institution. J Neurooncol. 2014;120:597\u2013605. https:\/\/doi.org\/10.1007\/s11060-014-1592-1.","journal-title":"J Neurooncol"},{"key":"3047_CR17","doi-asserted-by":"publisher","first-page":"e2483","DOI":"10.1212\/WNL.0000000000007529","volume":"92","author":"BM Andersen","year":"2019","unstructured":"Andersen BM, Miranda C, Hatzoglou V, DeAngelis LM, Miller AM. Leptomeningeal metastases in glioma: The Memorial Sloan Kettering Cancer Center experience. Neurology. 2019;92:e2483\u201391. https:\/\/doi.org\/10.1212\/WNL.0000000000007529.","journal-title":"Neurology"},{"key":"3047_CR18","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s00701-015-2344-5","volume":"157","author":"JH Noh","year":"2015","unstructured":"Noh JH, Lee MH, Kim WS, Lim DH, Kim ST, Kong DS, Nam DH, Lee JI, Seol HJ. Optimal treatment of leptomeningeal spread in glioblastoma: analysis of risk factors and outcome. Acta Neurochir (Wien). 2015;157:569\u201376. https:\/\/doi.org\/10.1007\/s00701-015-2344-5.","journal-title":"Acta Neurochir (Wien)"},{"key":"3047_CR19","doi-asserted-by":"publisher","first-page":"92","DOI":"10.4103\/2152-7806.192723","volume":"7","author":"DT Chan","year":"2016","unstructured":"Chan DT, Hsieh SY, Kam MK, Cheung TC, Ng SC, Poon WS. Pattern of recurrence and factors associated with cerebrospinal fluid dissemination of glioblastoma in Chinese patients. Surg Neurol Int. 2016;7:92. https:\/\/doi.org\/10.4103\/2152-7806.192723.","journal-title":"Surg Neurol Int"},{"key":"3047_CR20","doi-asserted-by":"publisher","first-page":"334","DOI":"10.3340\/jkns.2011.49.6.334","volume":"49","author":"JS Bae","year":"2011","unstructured":"Bae JS, Yang SH, Yoon WS, Kang SG, Hong YK, Jeun SS. The clinical features of spinal leptomeningeal dissemination from malignant gliomas. J Korean Neurosurg Soc. 2011;49:334\u20138. https:\/\/doi.org\/10.3340\/jkns.2011.49.6.334.","journal-title":"J Korean Neurosurg Soc"},{"key":"3047_CR21","doi-asserted-by":"publisher","unstructured":"Brain Tumor Registry of Japan (2005\u20132008). Neurol Med Chir (Tokyo). 2017;57: 9\u2013102. https:\/\/doi.org\/10.2176\/nmc.sup.2017-0001","DOI":"10.2176\/nmc.sup.2017-0001"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-03047-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-022-03047-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-03047-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T10:12:09Z","timestamp":1673345529000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-022-03047-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,7]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3047"],"URL":"https:\/\/doi.org\/10.1186\/s12883-022-03047-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1462235\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-1462235\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-1462235\/v3","asserted-by":"object"}]},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,7]]},"assertion":[{"value":"6 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in this study were in accordance with the ethical standards of the institutional and the 1964 Helsinki declaration and its later amendments. This study was approved by the internal review board of the National Cancer Center (2004\u2013066). Written informed consent was obtained from all individual participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}